GlobeNewswire Press

  1. Ventrus Announces Improved, FDA-Recommended Endpoints Proposed For Phase III Hemorrhoid Study 3/22/2011
    Ventrus BioSciences, Inc. (Nasdaq:VTUS) has filed a revised protocol with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) with new, more robust definitions for efficacy endpoints that were recommended by the FDA in a recent meeting with the company for the first pivotal study of the company's iferanserin (VEN 309) ointment, the first prescription product candidate for the treatment of hemorrhoids.
  2. Merrion Pharmaceuticals Plc Signs Feasibility And Option Agreement For 3 Drugs With International 'Top Ten' Pharmaceutical Company 12/7/2010
    Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the commencement of an oral drug delivery Feasibility and Option agreement with one of the world's top ten biggest pharmaceutical companies.
  3. ATMI Acquires European Biotech Firm To Expand Portfolio Of Bioprocess Manufacturing And Single-Use Technology Products For The Life Sciences Industry 11/4/2010
    ATMI, Inc. (Nasdaq:ATMI), announced today it has acquired the Belgian biotechnology firm Artelis S.A., an innovator in the area of highly-efficient bioprocesses and technologies for cell culture research and manufacturing scale-up. The acquisition complements ATMI's leadership in ultrapure single-use films, bioreactors, and mixing systems for characterizing, developing, and manufacturing biopharmaceuticals and extends its global capabilities to a broad range of biopharmaceutical process expertise.
  4. Momenta Pharmaceuticals Receives Four Therapeutic Discovery Project Credits Totaling Nearly $1M 11/4/2010
    Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that all four of its applications for the Qualifying Therapeutic Discovery Project Credit (Therapeutic Credit) were approved.
  5. Adamis Completes Acquisition Of Prostate Drug Candidates 10/26/2010
    Adamis Pharmaceuticals Corporation (OTCBB:ADMP), today announced the completion of the acquisition from Colby Pharmaceuticals of the remaining exclusive license agreements relating to two drug product candidates for the treatment of prostate cancer (PCa).
  6. Aceto Receives USDA Approval To Sell Companion Animal Vaccine In The United States 9/29/2010
    Aceto Corporation, a global leader in the sourcing, quality assurance, regulatory support, marketing and distribution of pharmaceuticals, nutraceuticals, specialty chemicals and crop protection products, today announced that it has received the USDA approval to sell its suppliers companion animal vaccine in the United States.
  7. Harbor BioSciences Apoptone® For Prostate Cancer Shows A Partial Overall Response 9/15/2010
    Harbor BioSciences, Inc. (Nasdaq:HRBR) a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.
  8. Acura Pharmaceuticals Named In Purported Class Action Securities Litigation 9/14/2010
    Acura Pharmaceuticals, Inc. (Nasdaq:ACUR - News) today announced that it and certain of its current and former executive officers have been named as defendants in a purported class action lawsuit filed on September 10, 2010 in the United States District Court for the Northern District of Illinois, Eastern Division.
  9. Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of SciClone Pharmaceuticals Inc. 8/12/2010
    Pomerantz Haudek Grossman & Gross LLP is investigating claims on behalf of investors of SciClone Pharmaceuticals Inc. ("SciClone" or the "Company") to determine whether it has violated federal securities laws by issuing false and misleading statements to its shareholders.
  10. Nabi Biopharmaceuticals Completes Third PentaStaph Milestone 8/11/2010
    Nabi Biopharmaceuticals (Nasdaq:NABI) announced today that it has successfully completed the technology transfer of program know-how associated with the sale of the PentaStaph™ vaccine candidate to GlaxoSmithKline Biologicals S.A. (GSK).